Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Tax Provisions (2016 - 2019)

Aptevo Therapeutics' Tax Provisions history spans 4 years, with the latest figure at -$999000.0 for Q3 2019.

  • For Q3 2019, Tax Provisions changed N/A year-over-year to -$999000.0; the TTM value through Sep 2019 reached -$12.9 million, changed N/A, while the annual FY2017 figure was -$12.8 million, 35.19% up from the prior year.
  • Tax Provisions for Q3 2019 was -$999000.0 at Aptevo Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.8 million in Q4 2017 and bottomed at -$13.8 million in Q3 2017.
  • The 4-year median for Tax Provisions is -$518000.0 (2015), against an average of -$1.3 million.
  • The largest YoY upside for Tax Provisions was 356.26% in 2017 against a maximum downside of 229366.67% in 2017.
  • A 4-year view of Tax Provisions shows it stood at $751000.0 in 2015, then tumbled by 246.74% to -$1.1 million in 2016, then surged by 356.26% to $2.8 million in 2017, then crashed by 135.38% to -$999000.0 in 2019.
  • Per Business Quant, the three most recent readings for APVO's Tax Provisions are -$999000.0 (Q3 2019), $2.8 million (Q4 2017), and -$13.8 million (Q3 2017).